Morgan Stanley Zentalis Pharmaceuticals, Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Morgan Stanley holds 1,611,567 shares of ZNTL stock, worth $5.41 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,611,567

Previous 1,950,722 17.39%

Holding current value

$5.41 Million

Previous $7.98 Million 25.87%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$2.9 - $4.57 $983,549 - $1.55 Million	-339,155 Reduced 17.39%	1,611,567 $5.91 Million
Q2 2024 Oct 17, 2024	BUY	$4.09 - $16.13 $3.74 Million - $14.7 Million	913,313 Added 88.04%	1,950,722 $7.98 Million
Q2 2024 Aug 14, 2024	BUY	$4.09 - $16.13 $3.74 Million - $14.7 Million	913,313 Added 88.04%	1,950,722 $7.98 Million
Q1 2024 Oct 17, 2024	SELL	$10.83 - $16.49 $9.89 Million - $15.1 Million	-913,313 Reduced 46.82%	1,037,409 $16.3 Million
Q1 2024 Aug 16, 2024	BUY	$10.83 - $16.49 $4.63 Million - $7.06 Million	427,926 Added 70.21%	1,037,409 $16.3 Million
Q1 2024 May 15, 2024	BUY	$10.83 - $16.49 $4.63 Million - $7.06 Million	427,926 Added 70.21%	1,037,409 $16.3 Million
Q4 2023 Aug 16, 2024	SELL	$9.84 - $20.13 $13.2 Million - $27 Million	-1,341,239 Reduced 68.76%	609,483 $9.23 Million
Q4 2023 Feb 13, 2024	BUY	$9.84 - $20.13 $628,411 - $1.29 Million	63,863 Added 11.7%	609,483 $9.23 Million
Q3 2023 Nov 15, 2023	BUY	$19.63 - $28.29 $839,084 - $1.21 Million	42,745 Added 8.5%	545,620 $10.9 Million
Q2 2023 Aug 14, 2023	BUY	$17.41 - $30.05 $4.03 Million - $6.96 Million	231,611 Added 85.38%	502,875 $14.2 Million
Q1 2023 May 15, 2023	BUY	$16.14 - $24.94 $2.22 Million - $3.44 Million	137,805 Added 103.26%	271,264 $4.67 Million
Q4 2022 Feb 14, 2023	BUY	$18.07 - $25.6 $651,694 - $923,264	36,065 Added 37.03%	133,459 $2.69 Million
Q3 2022 Nov 14, 2022	SELL	$20.23 - $31.73 $5.02 Million - $7.88 Million	-248,345 Reduced 71.83%	97,394 $2.11 Million
Q2 2022 Oct 27, 2022	BUY	$17.91 - $52.25 $3.01 Million - $8.77 Million	167,894 Added 94.4%	345,739 $9.72 Million
Q2 2022 Aug 15, 2022	BUY	$17.91 - $52.25 $3.01 Million - $8.77 Million	167,894 Added 94.4%	345,739 $9.72 Million
Q1 2022 Oct 27, 2022	SELL	$41.58 - $80.89 $6.98 Million - $13.6 Million	-167,894 Reduced 48.56%	177,845 $8.21 Million
Q1 2022 May 13, 2022	BUY	$41.58 - $80.89 $6.14 Million - $11.9 Million	147,701 Added 489.98%	177,845 $8.21 Million
Q4 2021 Feb 14, 2022	SELL	$66.92 - $84.79 $1.21 Million - $1.53 Million	-18,087 Reduced 37.5%	30,144 $2.53 Million
Q3 2021 Nov 15, 2021	BUY	$46.83 - $73.5 $2.26 Million - $3.54 Million	48,231 New	48,231 $3.21 Million

Others Institutions Holding ZNTL

# of Institutions

142

Shares Held

67.9M

Call Options Held

48.5K

Put Options Held

89.6K

View Full List

About Zentalis Pharmaceuticals, Inc.

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $191M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

More about ZNTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account